Cardiometabolic Risk Assessment with Labcorp NMR Labs
A page-by-page look at the report your patient receives: what each score measures, where it comes from, and how to use it in a visit. The patient sees the same pages with plain-language explanations; this guide adds the methods and evidence behind them.
What goes into the report
- Labcorp fasting panel: NMR LipoProfile with ApoB and the Lipoprotein Insulin Resistance (LP-IR) Score, standard lipid panel, GlycA, lipoprotein(a), hemoglobin A1C, and a basic metabolic panel including eGFR.
- Pre-assessment survey: anthropometrics and blood pressure, medications, smoking, family history, prior cardiovascular testing and events, familial hypercholesterolemia features, and the conditions that count as risk-enhancing factors.
- Guideline frameworks: AHA PREVENT equations, the risk-enhancing factors in the 2026 AHA/ACC/NLA cholesterol guideline, harmonized metabolic syndrome criteria, and the MetS severity score from MetS Calc.
The LP-IR Score is not valid on a non-fasting sample, so the draw must be fasting.
Reading the scales
Every scale runs green (lower risk) to red (higher risk). Category labels follow the source guideline or model, so they differ by domain:
| Domain | Categories |
|---|---|
| LP-IR Score (30–80+) | Optimal, Near Optimal, Intermediate, High, Very High |
| MetS severity percentile; PREVENT 10- and 30-year | Low, Borderline, Intermediate, High |
| 8-year T2D risk; overall CV risk | Low, Moderate, High, Very High |
| Hemoglobin A1C | Normal, Pre-Diabetes, Diabetes |
A white circle marks the current value; an X marks a category result. In follow-up reports a gray box marks the baseline value. In the metabolic syndrome table, yellow cells meet a criterion and red cells flag GlycA or ApoB above the high-risk cutoff.
Methods at a glance
Each score in the report comes from a published method or guideline. The one exception is how the overall cardiovascular risk category combines PREVENT with risk-enhancing factors, which is our own method.
| Measure | How it is derived | Refs |
|---|---|---|
| LP-IR Score | Weighted composite of six NMR lipoprotein measures: large VLDL-P, small LDL-P, large HDL-P, and mean VLDL, LDL, and HDL size. Scored 0 (most insulin sensitive) to 100 (most insulin resistant). Labcorp reports the reference-population 25th, 50th, and 75th percentiles as 27, 45, and 63. | 1, 2 |
| 8-year T2D risk | Sex-specific probability of incident type 2 diabetes from the LP-IR Score and fasting glucose, based on the Multi-Ethnic Study of Atherosclerosis. LP-IR has also predicted diabetes in the Women’s Health Study, JUPITER, and PREVEND. | 3–6 |
| MetS severity score | Sex- and race/ethnicity-specific continuous score from a confirmatory factor analysis of the five MetS components in NHANES adults, calculated with MetS Calc (metscalc.org). It behaves like a z-score and is reported as a percentile of U.S. adults. Higher scores predict incident diabetes, coronary heart disease, CVD, and ischemic stroke. | 9–16 |
| Metabolic syndrome | Harmonized criteria: waist above the sex- and ethnicity-specific cutoff, BP ≥130/85, fasting glucose ≥100, triglycerides ≥150, HDL-C <40 (men) or <50 (women), or drug treatment for that factor. Three or more criteria means metabolic syndrome. | 7, 8 |
| PREVENT risk | AHA PREVENT equations for 10-year and 30-year ASCVD risk, from the patient’s labs (including eGFR) and survey data. | Khan SS, et al. Circulation 2024 |
| Overall CV risk | Combines calculated PREVENT risk with every risk-enhancing factor in the 2026 AHA/ACC/NLA cholesterol guideline that applies to the patient, from labs, imaging history, and survey answers. | — |
| Lipoprotein goals | For the patient’s overall risk category, each LDL-C, non-HDL-C, and ApoB threshold goal is the lower of the guideline’s recommended percent reduction from baseline or its absolute target. ApoB is emphasized because particle number tracks risk reduction more closely than cholesterol content. | 17–22, 29, 30 |
| GlycA | NMR signal from glycan residues on acute-phase glycoproteins, a stable composite marker of systemic inflammation. Labcorp’s medical decision limit is 400 µmol/L. | — |
Page by page
Click any sample page to see it larger. The sample is an initial report.
Cover
Patient, report date, and ordering provider.
- Identifies the patient and the ordering clinician or organization
- Frames the report as decision support for shared decision-making, not a substitute for it
Click anywhere to close
Letter from the Chief Medical Officer
Sets the patient’s mental model before the numbers.
- Presents insulin resistance as the common driver of metabolic syndrome, type 2 diabetes, and ASCVD
- Explains that personal risk goes beyond major risk factors and population equations, and includes more than 30 guideline risk-enhancing factors
- Emphasizes that risk is modifiable and that response should be tracked with retesting
Click anywhere to close
Cardiometabolic Risk Summary
Four risk domains on one page for quick triage.
- LP-IR Score on a 30–80+ scale, the report’s anchor for insulin resistance
- MetS severity percentile, with category boundaries at the 25th, 50th, and 75th percentiles
- 8-year type 2 diabetes risk, with category boundaries at 10%, 15%, and 25%
- Overall cardiovascular risk category, from Low to Very High, after risk-enhancing factors are applied
Click anywhere to close
Metabolic Risk Details
Insulin resistance, metabolic syndrome criteria, and severity.
- LP-IR Score from the NMR lipoprotein profile. It reflects the lipoprotein changes of insulin resistance: more large VLDL and small LDL particles, fewer large HDL particles, larger VLDL, and smaller LDL and HDL.
- The five metabolic syndrome criteria with sex- and ethnicity-specific waist cutoffs. Criteria met are shaded yellow, and treatment for a factor counts as meeting it.
- Two additional high-risk factors shaded red when exceeded: GlycA >400 µmol/L and ApoB >110 mg/dL
- MetS severity score (MetS Calc), reported as a sex- and race/ethnicity-specific percentile of U.S. adults. Unlike the yes/no diagnosis, it captures severity below the diagnostic threshold and changes with treatment.
Click anywhere to close
Diabetes Risk Details
Current glycemic status and forward-looking diabetes risk.
- Hemoglobin A1C on a Normal, Pre-Diabetes, and Diabetes scale, with breakpoints at 5.7% and 6.5%
- LP-IR Score with its category scale
- Sex-specific 8-year probability of incident type 2 diabetes from LP-IR and fasting glucose (MESA), plotted on curves for minimum and maximum LP-IR across fasting glucose
- The curves show why LP-IR matters at a normal glucose: at the same fasting glucose, predicted risk rises steeply with insulin resistance
Click anywhere to close
Cardiovascular Risk Details
Calculated risk, risk-enhancing factors, overall category, and lipoprotein goals.
- PREVENT 10-year ASCVD risk with categories at 3%, 5%, and 10%, and 30-year risk with categories at 10%, 19%, and 24%. The report notes that lipid-lowering therapy is recommended at a 10-year risk of 5% or more, or a 30-year risk of 10% or more.
- Clinical risk-enhancing factors present for this patient, drawn from labs (such as LDL-C, non-HDL-C, ApoB, Lp(a), and GlycA), imaging history (such as a CAC score), and survey conditions (including sex-specific factors)
- Overall cardiovascular risk category, from Low to Very High, combining PREVENT with all applicable risk-enhancing factors in the 2026 AHA/ACC/NLA guideline
- Personalized LDL-C, non-HDL-C, and ApoB threshold goals for that category, shown next to baseline and current values. Each goal is the lower of the recommended percent reduction from baseline or the absolute target.
Click anywhere to close
Additional Topics for Discussion
Narrative talking points generated from the patient’s results and survey.
- Short explanations of findings that warrant discussion, such as severely elevated LDL-C or ApoB, elevated GlycA, or whether noninvasive imaging may be a reasonable next step
- Links to patient education pages for each topic, and to the reference list
Click anywhere to close
Tracking Charts
Serial values against goals, designed for retesting.
- Metabolic risk tracking: the five MetS components, the severity score, and GlycA at each test
- Diabetes risk tracking: A1C, fasting glucose, LP-IR, and estimated 8-year risk
- Atherogenic lipoprotein tracking: LDL-C, non-HDL-C, and ApoB against each threshold goal
- A QR code on the divider page links the patient to a reference page for every topic in the report
Pre-Assessment Survey Responses
Every patient-reported input that feeds the calculations.
- Height, weight, waist, BMI, and blood pressure, which drive the MetS criteria, MetS severity score, and PREVENT
- Blood pressure and glucose history and treatment, smoking, and family history of diabetes and premature ASCVD
- Prior vascular testing (CAC, CTA, carotid ultrasound, ABI, angiography) and any events or procedures
- LDL-C history and familial hypercholesterolemia features, current lipid therapy, and conditions that count as risk-enhancing factors, including sex-specific factors
Click anywhere to close
Labcorp Lab Report
The complete Labcorp report, unaltered.
- NMR LipoProfile: ApoB, the LP-IR Score and its six component measures with reference percentiles, and the standard lipid panel (LDL-C by the NIH equation)
- GlycA and lipoprotein(a)
- Hemoglobin A1C and the basic metabolic panel, including fasting glucose and eGFR
Click anywhere to close
Follow-up reports
Follow-up reports keep the same structure and add the patient’s baseline beside each current value.
- On every scale, a gray box marks the baseline value and a white circle marks the current value
- Detail tables show baseline and current columns, colored by the same criteria
- Lipoprotein threshold goals stay anchored to the baseline values, so percent-reduction goals don’t drift as values improve
- Tracking charts add a point for each test. The report suggests reassessing every 3 to 6 months, depending on risk.

Click anywhere to close
Click anywhere to closeSee it with your own patients
Ordering takes about 30 seconds, and we deliver the completed report in a few days. We’re happy to walk through a sample with you.
Sample pages are from a real report with all personal details removed. Reference numbers match the list on our references page. Precision Health Reports supports, and does not replace, clinical judgment.